| 1 |
32975370 | Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts. | 2020 Dec |
1 |
| 2 |
28866094 | Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer. | 2017 Nov 1 |
1 |
| 3 |
25342139 | BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. | 2015 Feb |
1 |
| 4 |
26137449 | Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. | 2015 |
1 |
| 5 |
26567773 | Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer. | 2015 Nov 16 |
2 |
| 6 |
24567366 | DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. | 2014 May |
1 |
| 7 |
21286012 | Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? | 2011 Feb |
2 |
| 8 |
21124782 | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. | 2010 Nov 29 |
1 |